Pyrotinib dosing study for HER2-positive advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 to 70 with HER2-positive breast cancer that has spread to other parts of the body (stage IV).
- You have not received any previous cancer treatment for this recurrence or spread.
- You have at least one tumor that can be measured on a scan.
- Your overall health is good enough for daily activities (ECOG score 0 or 1).
- Your blood counts, liver, kidney, and thyroid function are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
This study looks at how well the drug pyrotinib works in people with advanced breast cancer that has spread and tests positive for HER2. HER2 is a protein that can make cancer cells grow, and pyrotinib targets it. If you have this type of breast cancer, this study may show if the treatment helps you.
This study tests giving certain targeted drugs before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach helps reduce tumor size and improve outcomes.
This trial tests a new combination of two targeted drugs (entinostat and pyrotinib) with hormone therapy for people with advanced, triple-positive breast cancer whose disease has progressed after trastuzumab (Herceptin). The goal is to see if this approach works better than current options.
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
This trial tests a targeted drug called pyrotinib for women with HER2-positive breast cancer that hasn't spread far. It aims to see if adding this drug to standard treatment helps improve outcomes before and after surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.